Bonesupport Holding Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Bonesupport Holding de 23.6% y 26.7% por año respectivamente. Se prevé que el BPA crezca en un 23.1% al año. Se espera que la rentabilidad financiera sea de 37% en 3 años.

Información clave

19.5%

Tasa de crecimiento de los beneficios

1.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	38.7%
Tasa de crecimiento de los ingresos	27.1%
Rentabilidad financiera futura	33.6%
Cobertura de analistas	Low
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Mar 31

Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares

Mar 04

One Bonesupport Holding AB (publ) (STO:BONEX) Analyst Just Cut Their EPS Forecasts

Mar 02

What Kind Of Investors Own Most Of Bonesupport Holding AB (publ) (STO:BONEX)?

Feb 28

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Feb 07

Executive VP of R&D Michael Diefenbeck Just Bought 2.6% More Shares In Bonesupport Holding AB (publ) (STO:BONEX)

Jan 17

The Bonesupport Holding (STO:BONEX) Share Price Has Gained 283%, So Why Not Pay It Some Attention?

Dec 31

What Can We Make Of Bonesupport Holding's (STO:BONEX) CEO Compensation?

Dec 13

Analysts Expect Breakeven For Bonesupport Holding AB (publ) (STO:BONEX) Before Long

Nov 25

Previsiones de crecimiento de beneficios e ingresos

OM:BONEX - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,545	474	335	357	2
12/31/2025	1,188	311	331	301	3
12/31/2024	857	174	72	89	3
3/31/2024	656	267	0	7	N/A
12/31/2023	591	245	-24	-18	N/A
9/30/2023	522	214	-40	-37	N/A
6/30/2023	448	-30	-66	-63	N/A
3/31/2023	382	-51	-51	-48	N/A
12/31/2022	329	-68	-50	-47	N/A
9/30/2022	287	-72	-62	-58	N/A
6/30/2022	257	-71	-72	-68	N/A
3/31/2022	234	-82	-81	-77	N/A
12/31/2021	213	-86	-87	-83	N/A
9/30/2021	205	-88	-90	-88	N/A
6/30/2021	198	-96	-89	-87	N/A
3/31/2021	182	-92	-88	-86	N/A
12/31/2020	181	-101	-103	-100	N/A
9/30/2020	174	-115	-121	-117	N/A
6/30/2020	165	-127	-143	-139	N/A
3/31/2020	166	-151	-155	-150	N/A
12/31/2019	155	-161	-168	-164	N/A
9/30/2019	132	-166	-181	-176	N/A
6/30/2019	108	-191	-193	-189	N/A
3/31/2019	98	-182	-180	-177	N/A
12/31/2018	97	-176	-174	-172	N/A
9/30/2018	101	-182	-152	-147	N/A
6/30/2018	119	-146	-133	-128	N/A
3/31/2018	128	-132	-116	-112	N/A
12/31/2017	129	-129	N/A	-108	N/A
9/30/2017	132	-112	N/A	-112	N/A
6/30/2017	126	-124	N/A	-106	N/A
3/31/2017	114	-124	N/A	-103	N/A
12/31/2016	105	-110	N/A	-82	N/A
12/31/2015	62	-60	N/A	-65	N/A
12/31/2014	41	-75	N/A	-46	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (23.6% al año) de BONEX es superior a la tasa de ahorro (0.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (23.6% al año) de BONEX crezcan más rápidamente que el mercado Swedish (13.1% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de BONEX crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (26.7% al año) de BONEX crezcan más rápidamente que los del mercado Swedish (1.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (26.7% al año) de BONEX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BONEX sea alta dentro de 3 años (37%)

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Bonesupport Holding Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 14% to kr293

Consensus EPS estimates fall by 24%, revenue upgraded

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Forecast breakeven date moved forward to 2023

Price target increased by 17% to kr142

Recent updates

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock

Third quarter 2021 earnings released

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Bonesupport Announces Supplementary US Denovo Application Submitted

Chief Executive Officer recently bought kr343k worth of stock

Price target decreased to kr65.00

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Insider recently bought kr401k worth of stock

Chairman of the board recently bought kr1.6m worth of stock

Second quarter 2021 earnings released

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr210k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Chief Executive Officer recently bought kr407k worth of stock